Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 1;39(11):1641-1649.
doi: 10.1097/QAD.0000000000004238. Epub 2025 May 20.

The natural history of anal high-grade squamous intraepithelial lesions among MSM and transgender women in an acute HIV cohort in Thailand

Supanat Thitipatarakorn  1 , Nipat Teeratakulpisarn  1 , Siriporn Nonenoy  1 , Aphakan Klinsukontakul  1 , Sujittra Suriwong  1 , Sumitr Tongmuang  1 , Piranun Hongchookiat  1 , Napasawan Chinlaertworasiri  1 , Pravit Mingkwanrungruang  1 , Carlo Sacdalan  2   3 , Kultida Poltavee  2 , Nitiya Chomchey  2 , Tippawan Pankam  4   5 , Stephen J Kerr  6   7   8 , Reshmie A Ramautarsing  1 , Donn Colby  1 , Nittaya Phanuphak  1   9
Affiliations

The natural history of anal high-grade squamous intraepithelial lesions among MSM and transgender women in an acute HIV cohort in Thailand

Supanat Thitipatarakorn et al. AIDS. .

Abstract

Objective: To describe the incidence and clearance rates of anal high-grade squamous intraepithelial lesions (HSIL) among MSM and transgender women who initiated immediate antiretroviral therapy during acute HIV acquisition.

Design: A prospective cohort study of MSM and transgender women diagnosed with acute HIV acquisition in Bangkok, Thailand.

Methods: Participants who were enrolled from May 2017 to June 2020 underwent anal human papillomavirus (HPV) genotyping, high-resolution anoscopy, and anal biopsies as indicated, at baseline and 6-monthly follow-up visits.

Results: Among 89 MSM and 4 transgender women (median age 26 years), the anal HSIL incidence rate was 22.7 per 100 person-years over 180.9 person-years, while the clearance rate was 119.4 per 100 person-years over 32.7 person-years. After adjusting for age, smoking, and baseline CD4 + cell count, incident anal HSIL was greater in those with persistent HPV 16 [adjusted hazards ratio (aHR) 14.98, 95% confidence interval (CI) 1.73-129.48], nonpersistent HPV 16 (aHR 15.12, 95% CI 1.84-124.50), persistent non-16 cancer-associated HPV types (aHR 17.90, 95% CI 2.34-136.74), and nonpersistent non-16 cancer-associated HPV types (aHR 10.65, 95% CI 1.34-84.93) compared to participants with consistently negative cancer-associated HPV. Persistent (aHR 0.17, 95% CI 0.04-0.66) and nonpersistent HPV 16 (aHR 0.22, 95% CI 0.05-0.98) were associated with lower HSIL clearance likelihood.

Conclusion: Among predominantly young participants initiating antiretroviral therapy during acute HIV acquisition, anal HSIL showed high incidence yet markedly high clearance rates. Anal HPV 16 infection increased risk of incident anal HSIL and decreased lesion clearance. HPV vaccination and HSIL screening/treatment should be implemented despite rapid antiretroviral therapy initiation.

Keywords: HIV; antiretroviral therapy; human papillomavirus viruses; precancerous conditions; sexual and gender minorities.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve of the cumulative probability of incident anal high-grade squamous intraepithelial lesions stratified by anal cancer-associated human papillomavirus infection status.
Fig. 2
Fig. 2
Kaplan–Meier curve of the anal high-grade squamous intraepithelial lesion clearance stratified by anal cancer-associated human papilloma virus infection status.
See this image and copyright information in PMC

References

    1. Colón-López V, Shiels MS, Machin M, Ortiz AP, Strickler H, Castle PE, et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol 2018; 36:68–75. - PMC - PubMed
    1. Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale. Int J Cancer 2021; 148:38–47. - PMC - PubMed
    1. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203–1211. - PubMed
    1. Deeken JF, Tjen-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55:1228–1235. - PMC - PubMed
    1. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012; 136:1266–1297. - PubMed

MeSH terms